Skip to contentSkip to filters

We use cookies for analytics.

Collaborative grant, Call number HORIZON-HLTH-2027-01-DISEASE-08

Development of innovative antimicrobials against pathogens resistant to antimicrobials

European Commission (Horizon Europe)

  • €8,000,000 – €10,000,000
  • Early independent researcher · Mid-career researcher · Established researcher
  • Institution applies
  • Pharmacology, Microbiology and
Related content

About

Horizon Europe research and innovation action to advance existing therapeutic candidates, including antibody-based therapies, against one priority resistant pathogen: CRAB, carbapenem- or third-generation-cephalosporin-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, MRSA, or drug-resistant Aspergillus fumigatus or Candida. Candidates must meet a WHO innovation criterion; phage therapies are out of scope.

Topics

Eligibility

Covers: Estimated EU contribution of EUR 8–10 million per project; about five projects from a EUR 44.2 million topic budget.

Legal entities in EU Member States and Horizon Europe associated countries; other countries per Horizon Europe General Annex B.

ec.europa.eu

Consortia meeting Horizon Europe eligibility; legal entities established in the United States are also eligible for Union funding under this topic. Single-stage call.

Source: ec.europa.eu